T he vascular endothelium is an important modulator of smooth muscle responsiveness, playing a critical role by releasing both vasoconstricting and vasodilating substances.' Endothelium-derived relaxing factor (EDRF), a potent vasodilator, is released when the endothelium is stimulated by agonists such as acetylcholine, bradykinin, and substance p.2 EDRF is believed to be nitric oxide (NO).3 It has been repeatedly demonstrated that both animal and human atherosclerotic vessels have an impaired response to endotheliumdependent vasodilation. [4] [5] [6] In atherosclerotic vessels, the increased sensitivity to vasoconstricting substances is left unopposed by the impaired action of EDRF.7.8 It has been proposed that this imbalance may predispose atherosclerotic coronary arteries to vasoconstriction. 9 Several studies have shown that EDRF-mediated arterial dilation is impaired in the presence of hypercholesterolemia prior to the development of any obvious pathologic modifications in the vessel wall. This has been demonstrated in hypercholesterolemic animal models as well as in arteries exposed to lipoproteins in vitro. 10, 11 In hypercholesterolemic humans, blunted vasodilation in response to the cholinergic agonist methacholine has been observed in vivo in forearm arterial resistance vessels, where atherosclerosis is not a common finding. 12 These results suggest that hypercholesterolemia per se may impair EDRF action before frank atheroma formation has occurred and could therefore be involved in the development and exacerbation of disease processes associated with increased peripheral resistance. Low-density lipoproteins (LDLs) in particular have been shown to cause a decrease in EDRFmediated vasodilation,13 and oxidized LDLs may be responsible for inactivation of EDRF.14,15
We tested the hypothesis that hypercholesterolemia impairs EDRF-mediated vasodilation in vivo in humans by the functional interaction between the high concentrations of lipoproteins in the plasma and the intact endothelium. We chose to investigate the responsiveness of human veins in vivo in hypercholesterolemic subjects; in this experimental system, endothelial damage and other pathologic alterations are very unlikely. Human veins do not develop atherosclerosis unless they are exposed to the same hemodynamic conditions as arteries, such as occurs in vein grafts. 16 We examined bradykinin-mediated vasodilation in markedly hypercholesterolemic subjects using the human hand-vein compliance technique, which has the advantage of allowing construction of complete dose-response curves. In addition, we investigated the effect of lowering plasma cholesterol concentrations with lovastatin on venous responsiveness to bradykinin.
Methods

Subjects
Studies were performed on 25 subjects (age range, 22 to 80), 13 between the position of the core before and after inflation of the blood pressure cuff positioned on the same arm). The central aperture of the LVDT contains a freely movable metallic core; the LVDT, which contains three coiled wires creating an electromagnetic field, detects the movements of the metallic core when the vein enlarges after inflation of the cuff. The signal output of the LVDT is linearly proportional to the vertical movement of the core and is amplified and recorded on a strip-chart recorder. Doses of drugs are expressed as rates of infusion. Each dose was infused for a minimum of 5 minutes, which has been shown to be sufficient to reach the maximum effect at each infusion rate,17 after which a reading was taken. Results are presented as normalized dose-response curves, in which venodilation is plotted against the logarithm of the dose. The dilation of the vein at baseline after 30 minutes of saline infusion was defined as 100% relaxation. Phenylephrine, a selective a,-agonist, was used to preconstrict the hand vein. Phenylephrine was infused in the dose range of 12 to 7917 ng/min; the dose of phenylephrine that produced 80% constriction was determined. This degree of preconstriction was defined as 0% dilation. This dose of phenylephrine was then infused at a constant rate during the subsequent administration of the vasodilating drugs, bradykinin and NTG. The vasodilation produced by these drugs was calculated as a percentage of the range between 100% and 0% vasodilation. Blood pressure and heart rate were monitored in the opposite arm with a Dinamap Blood Pressure Monitor model 845 (Critikon, Tampa, FHa).
Study Design
After an 80% preconstriction of the vein was obtained with phenylephrine, a complete dose-response curve to bradykinin was constructed (doses ranging from 0.25 to 508 ng/min). A washout period of 45 minutes followed, during which indomethacin alone was infused locally at a rate of 5.4 gg/min to inhibit prostaglandin synthesis. In preliminary experiments, we verified that bradykinin is indeed an endothelium-dependent vasodilator in human veins; in three subjects, bradykinin gave a maximal response of 90±22, which was reduced by infusion of NG-monomethyl-L-arginine (25 The two groups of subjects were very similar in age and sex distribution. They significantly differed only in total cholesterol and low-density lipoprotein serum values. Values are given as mean±SD. Ranges are given in parentheses.
(1583 ng/min), previously shown to produce a maximal response20 was infused while continuing the same dose of phenylephrine. The NTG challenge was performed in 21 of the 25 volunteers (10 hypercholesterolemic and 11 normocholesterolemic).
Blood pressure and heart rate were not affected by infusion of the above stated doses of bradykinin, NTG, and phenylephrine.
Five of the hypercholesterolemic subjects were treated with lovastatin at a dose of 20 mg once a day. Serum lipids were measured between days 17 and 28 of treatment. A study, with the same protocol described above, was repeated when the total cholesterol concentration had dropped below 240 mg/dL. One subject did not have an adequate response to this dose of lovastatin and underwent a second month of treatment with 40 mg lovastatin once a day before plasma cholesterol decreased to less than 240 mg/dL. Materials All drugs were diluted in normal saline. The following drugs were used: phenylephrine hydrochloride (1% injection) ( We also compared bradykinin and nitroglycerin responsiveness by calculating the ratio between their respective maximal responsiveness in each of the individual subjects. The ratio in the hypercholesterolemic group was 68±20% and in the normocholesterolemic was 72±27% (P=.37), confirming the conclusion that the bradykinin response is not changed when corrected for the response to NTG. We also performed a linear regression of the maximal bradykinin response versus NTG response and found a positive correlation with r=.73 and P<.05 for the hypercholesterolemic and with r=.56 and P=.05 for the normocholesterolemic; this shown in Table 2 . Lovastatin significantly decreased total cholesterol and LDL, without changing concentrations of TG and HDL. The decrease in cholesterol level was 20%, as typically occurs after 1 month of treatment.24 Emu to bradykinin decreased from 103+52% to 80±28% after treatment with lovastatin (P=.21); E..,C in the presence of indomethacin decreased from 130± 46% to 85±28% (P=.10). Discussion We tested the hypothesis that hypercholesterolemia impairs endothelium-dependent vasodilation in response to bradykinin in human veins in vivo. Veins do not develop atherosclerosis unless they are exposed to the same hemodynamic stress and oxygen tension as arteries, such as occurs in vein grafts.l6,25 Therefore, the venous bed is appropriate for testing functional alterations caused by the interaction between elevated plasma lipoproteins and a normal endothelium. Surprisingly, we found that bradykinin-mediated venodilation not only was not impaired by hypercholesterolemia but was even greater than in normocholesterolemic controls.
The endothelium has an obligatory role in mediating relaxation to bradykinin and to other substances such as acetylcholine, histamine, ATP, and substance p.2 The vasodilating substance released by the endothelium is termed EDRF and was identified as NO3 and is synthesized from L-arginine by endothelial NO-synthase.2627 EDRF stimulates synthesis of cGMP in vascular smooth muscle leading to dilation of the vessel. 28 In human veins, bradykinin-mediated vasodilation is greatly, but not completely, inhibited by both N0-monomethyl-Larginine,29 a specific inhibitor of NO-synthase,27 and methylene blue,'9 an inhibitor of soluble guanylyl cyclase. A component of bradykinin-mediated vasodilation is thought to be due to the release of prostaglandins.30 For this reason, each subject in the study had a second dose-response curve to bradykinin generated in the presence of indomethacin, a cyclooxygenase inhibitor, to investigate the component of the response that was due exclusively to EDRF release. The dose of indomethacin used, 5.4 jg/min, results in an estimated final concentration of 2.4 ,ug/mL in the vein, based on an average blood flow of 2.5 mL/min, typically found in dorsal hand veins (unpublished observations). This concentration (7*10-6 mol/L) is similar to that reported in the literature to be effective for blocking cyclooxygenase. 30, 31 Indomethacin caused a modest but significant twofold rightward shift of the bradykinin dose-response curve in normocholesterolemic subjects, suggesting that prostaglandin release contributes partially to bradykinin-mediated venodilation in humans. Interestingly, indomethacin did not significantly change the response to bradykinin in hypercholesterolemic subjects; instead, there was a trend toward a greater E.a and lower ED50 of bradykinin after indomethacin infusion. This suggests that in the presence of hypercholesterolemia, production of dilating prostaglandins may be diminished after stimulation with bradykinin; it is also possible that vasoconstrictor prostaglandins are preferentially released. Human arteries have a reduced synthesis of PGI2 in atherosclerosis.32 A similar abnormality has been shown in the aorta after a high-cholesterol diet for 4 weeks in rabbits.33 In porcine coronaries with moderate atherosclerosis the endothelium-dependent relaxation to serotonin and ADP is enhanced after exposure of the vessels to indomethacin, probably due to an endoperoxide intermediate of the cyclooxygenase pathway. 31 The synthesis of vasoconstricting endoperoxides, such as thromboxane B2, is increased in aortas from cholesterol-fed rabbits.34 '35 Atherosclerosis impairs EDRF-mediated relaxation because of the loss of endothelium and possibly because of impaired diffusion of EDRF through the thickened intima.4-6 Recent-onset, mild hypercholesterolemia impairs EDRF-mediated vasodilation in coronary arteries from swine fed for only 9 weeks with a high-cholesterol diet10 and in rabbit abdominal aortas." In humans with elevated LDL and angiographically normal coronary arteries, acetylcholine infused into the coronary vessels produces a modest coronary constriction compared with the vasodilation produced in normal subjects.36 In hypercholesterolemic subjects, forearm arteries have a smaller increase in blood flow, as measured by venous occlusion plethysmography, after infusion of methacholine.'2 It is usually assumed that certain arterial beds, such as resistance vessels12 and coronary microcirculation vessels,37 do not develop atherosclerosis. of absence of lesions; using more sophisticated techniques, such as transmission electron microscopy, alteration in the intima and in the elastica of vessels can be found after only 2 weeks of hypercholesterolemia.38
A number of possible mechanisms may be involved in the blunted efficacy of endothelium-dependent vasodilators to relax arterial smooth muscle. EDRF (NO) is synthesized from L-arginine.26,27 Administration of L-arginine restored acetylcholine-mediated vasodilation in vivo in hindlimbs of hypercholesterolemic rabbits,39 suggesting a reduction of synthesis and release of EDRF. However, in another study, EDRF, bioassayed after stimulation by acetylcholine, was not decreased even if vasodilation was impaired.40 Indeed, it has been suggested that NO production was markedly increased after acetylcholine challenge in thoracic aortas from hypercholesterolemic rabbits, even though relaxation was diminished. 41 The authors hypothesized that the receptor-mediated signal-transduction pathway that leads to the activation of the NO synthase is preserved. A subsequent step in the pathway leading to vasodilation is impaired, possibly leading to upregulated release of EDRF because of decreased response of the smooth muscle.4' Atherosclerotic lesions are rich in ox-LDLs,42
and ox-LDLs may directly inactivate EDRF.13,15 Furthermore, superoxide anions and hyperoxia inactivate EDRF. 43, 4 Our results demonstrate that hypercholesterolemia does not affect endothelium-dependent vasodilation in veins, in contrast to what has been reported in arteries. Given the low oxygen tension in veins, the oxidative damage and depletion of certain chemical groups associated with lipoprotein metabolism and oxidation and the release of free radicals by the macrophages may be lacking. EDRF is believed to be a nitrosylate compound in which NO is incorporated, most likely a nitrosothiol molecule.4546 If thiol groups are needed for synthesis of EDRF, the oxidative damage associated with macrophage activation during accumulation of lipids47 could deplete cells of reduced sulfhydryl groups and impair incorporation of NO in the more potent nitrosylate molecule.
Other factors could explain the difference between veins and arteries; different endothelium-derived dilating factors have been identified, among which is endothelium-dependent hyperpolarizing factor (EDHF).'
The relation between EDRF and EDHF is not clear yet, but arteries may lose endothelium-dependent mechanism of dilation earlier than veins.
The increased response to NTG in subjects with hypercholesterolemia is an unexpected and interesting finding. Since these subjects were also more sensitive to bradykinin, the results raise the hypothesis that there may be enhanced sensitivity to cGMP-dependent vasodilation in veins of hypercholesterolemic humans. However, to address the biochemical mechanism of the enhanced responsiveness to NTG, it would be necessary to measure directly the different components of the vasodilating cascade in isolated blood vessels.
While in some studies response to bradykinin in hypercholesterolemia is affected,5 there are reports of conserved response to bradykinin3' and to A2318748 in hypercholesterolemic porcine coronary arteries. In studies conducted in humans in vivo,1236 acetylcholine However, there is some disagreement on the definition has been used to test endothelium-dependent vasodilation. Acetylcholine acts as a vasoconstrictor on smooth muscle cells and a vasodilator through promoting release of EDRF, and a minimal impairment of endothelium function could therefore be unmasked by the prevailing vasoconstriction.
The results with lowering serum cholesterol with lovastatin support the overall conclusions of this study.
We observed a clear trend, although not statistically significant at the P<.05 level, toward a decreased responsiveness to bradykinin after plasma cholesterol concentrations were decreased with lovastatin.
Our study demonstrates that hypercholesterolemia by itself is not sufficient to cause impaired EDRF-dependent vasodilation in blood vessels. Further investigation of the difference in interaction of lipoproteins with venous and arterial blood vessels will be important to determine the actual mechanism by which hypercholesterolemia affects endothelial function.
